Cryoport, Inc. (CYRX) stock analysis

P/E against its history

Not enough price and earnings history to compare.

P/E against the industry

Needs positive earnings and enough profitable companies in the industry.

EV/EBITDA against its history

Needs positive EBITDA and price history.

P/B below the industry

Cryoport's price-to-book of 2.15 is below the Drugs median of 2.29.

Trading above fair value

The share price of $20.56 is above our fair value estimate of $16.42.

Margin of safety under 20%

The price is 25.2% above fair value, so there is no margin of safety.

Revenue growing under 10% a year

Revenue grew -9.4% a year over the last three fiscal years, short of the 10% we look for.

EPS growth over 3 years

Needs positive EPS three years ago and today.

Earnings acceleration

Needs positive net income now, a year ago and five years ago.

Growing faster than the industry

Revenue grew 11.8% over the last twelve months; the Drugs median is 8.0%.

Guidance raised

Cryoport raised its full-year full-year revenue guidance outlook on May 4, 2026.

Gross margin slipping

Gross margin was 46.9% over the last twelve months, against 46.9% a year earlier.

Return on equity under 15%

Return on equity was -8.3% over the last twelve months and averaged -17.5% over five years; we look for 15% on both.

Return on capital under 10%

Return on invested capital was -32.9%, below the 10% that usually covers the cost of capital.

Return on equity above the industry

Cryoport's return on equity of -8.3% is above the Drugs median of -58.9%.

Earnings over 5 years

Needs positive net income five years ago and in the latest year.

Net margin above its 5-year average

Net margin was -21.5% over the last twelve months, against a 5-year average of -45.5%.

Net margin above the industry

Cryoport's net margin of -21.5% is above the Drugs median of -53.0%.

Low debt

Debt is 0.2% of shareholders' equity, under the 40% we consider low.

Debt falling against equity

Debt to equity fell from 1.3% five years ago to 0.2%.

Debt covered by cash flow

Operating cash flow over the last twelve months equals 1161% of total debt.

Interest not well covered

Operating income covers interest expense -18.3 times; we look for at least 5.

Short-term assets cover short-term debts

Current assets are 2.04 times current liabilities.

Elevated bankruptcy risk

The Altman Z-score is 1.46; above 3 is the safe zone and below 1.8 the distress zone.

No dividend

Cryoport has not paid a dividend in the last twelve months.

Yield against Treasuries

No dividend.

Yield against the market

No dividend.

Dividend stability

No dividend.

Earnings cover

No dividend.

Cash-flow cover

No dividend.